Web14 Jan 2024 · For research use only. We do not sell to patients. Smurf1-IN-A01. CAS No. : 1007647-73-5. Biological Activity：Smurf1-IN-A01 (A01) is an ubiquitin ligase Smad … Web24 Nov 2009 · The HECT-type E3 Smad ubiquitination regulation factor 1 (Smurf1) functions in regulation of cell polarity and bone homeostasis by targeting Smads, Runx2, RhoA and MEKK2 for ubiquitination and degradation. In a yeast two-hybrid screening, we identified TNF receptor-associated factor 4 (TRAF4) as a candidate substrate and was further validated. …
Anti-fibrotic therapy in the treatment of IPF: Ongoing concerns and …
WebUbiquitination Assay—2T3 cells were transfected with M-Smad1andtreatedwithTNFfor72h MG132forthelast 4 h of TNF treatment. Cell lysates were incubated with anti … WebTaken together, we show that Smurf1 promotes tumor progression via PTEN, and combined treatment of Smurf1 knockdown with mammalian target of rapamycin (mTOR) inhibition reduces tumor progression. These results identify a unique role of Smurf1 in mTOR inhibitor resistance and provide a strong rationale for combined therapy targeting GBM. richfield rail
OTUB1 promotes osteoblastic bone formation through stabilizing …
WebSmurf1 was originally identified as an E3 ubiquitin ligase that interacted with Smad1 and Smad5 through a specific interaction between the Smurf1 WW domain and the PY motif … Web18 Mar 2024 · IPF is a chronic, progressive, irreversible and usually fatal interstitial lung disease 1 which affects approximately 100,000 people in the US. 2 On average, patients who are diagnosed with IPF live between two and five years from diagnosis, given the limited medicines available to treat the disease. 1 The FDA grants ODD status to medicines … Web18 Mar 2024 · The US Food and Drug Administration (FDA) has granted Orphan Drug Designation (ODD) for saracatinib, a potential new medicine for the treatment of … red patent dr martens shoes